Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

摘要

NZ 601581 The disclosure relates to the use of an imidazo-pyrazin derivative, a pyridin-purine-carboxamide derivative, or a triazol-pyridin-pyrazin derivative as a TOR kinase inhibitor for treating and/or preventing non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome. Particularly disclosed is the use of a 3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one derivative of formula (Ie), which is a TOR kinase inhibitor suitable for treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome characterized by (i) a LKBI gene or protein loss or mutation, relative to wild type, (ii) a AMPK gene or protein loss or mutation, relative to wild type, or (iii) a reduced level of pAMPK protein, AMPK activity, or both, relative to wild type.